Guangdong Medical Valley Hosts Industry Linkage Salon on Targeted Therapeutics and Intellectual Property Utilization & Protection

Jia-Sheng Xie, Executive President of Guangdong Medical ValleyIn the speech, it was emphasized that at present, the life science industry in the Guangdong-Hong Kong-Macao Greater Bay Area is rapidly emerging. Nansha, as the geometric center of the Greater Bay Area, bears the important mission of promoting the high-quality development of the biopharmaceuticals industry. Having deeply cultivated the biopharmaceuticals industry in the Greater Bay Area for many years, Guangdong Medical Valley has nurtured and incubated a group of high-quality targeted drug research and development enterprises, profoundly recognizing the dual importance of "innovative breakthroughs" and "intellectual property protection" in industrial development. This salon brings together intellectual property agencies, corporate representatives, and legal experts, serving not only as an accurate docking of industrial resources but also as an in-depth exchange of experiences in intellectual property protection.

Distinguished Professor Zhenglong Gu of Fudan UniversityFocusing on the association between mitochondrial DNA mutations and diseases, he elucidated their physical and biological foundations and revealed their critical impact on childhood disorders such as autism, age-related diseases, and aging. Subsequently, he presented therapeutic strategies including high-throughput drug screening and "molecular glue" development, along with related patents and mouse experimental results, providing significant support for mitochondrial disease research and clinical translation.

Wang Yong, Senior Partner of Jincheng Tongda Law FirmCentering on four core aspects. First, provide suggestions for the patent layout of target proteins and targeted drugs, clarifying the protection objects such as protein kinases, key points for compound patent applications, and directions for small-molecule drug derivative layouts. Then, analyze intellectual property protection and transformation risks of targeted drugs, covering issues like technical secret protection, ownership of results, asset evaluation, and corresponding solutions. Finally, using the patent dispute between BeOne Medicines and AbbVie as an example, offer insights into handling Sino-US patent disputes, providing comprehensive intellectual property guidance for the industry.

Xu Xuejie, Vice President of Manufacturing at TiankeyaIt was pointed out that the CGT industry shows a positive trend in terms of policies, technology, and the market. In 2025, CDE issued ATMP-related documents consecutively to improve regulation, while technological breakthroughs have made previously untreatable diseases like leukemia treatable. The global and Chinese CGT markets are experiencing significant growth, with the compound annual growth rate of China’s cell and gene therapy market reaching 276% from 2020 to 2025, and CAR-T products showing outstanding performance. However, the industry also faces challenges such as complex processes, high costs, and an imperfect supply chain. Future developments will focus on broadening indications, improving accessibility, and innovating processes, while continuously advancing clinical trials and product commercialization.

In a relaxed and pleasant atmosphere, the attending guests engaged in enthusiastic exchanges, conducting in-depth discussions on technological development, resource sharing, and policy support.

In the future, Guangdong Medical Valley will continue to build a high-quality communication platform, promote exchanges and cooperation through activities, and contribute to the high-quality development of the biopharmaceutical industry by integrating resources from all parties.